Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)

This study has been terminated.
(Termininated for business reasons)
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 5, 2006
Last updated: December 17, 2015
Last verified: December 2015
To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Fluticasone
Drug: Comparator: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Standardized Dyspnea Score at Isotime During Exercise [ Time Frame: 2 Weeks ]

    Difference in standardized dyspnea rating at isotime during constant load exercise in patients with COPD between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.

    Isotime is the duration of the shortest exercise test on all treatment days (or the longest exercise time point common to all constant-load exercise tests). The standardized dyspnea score will be measured with the modified 10-point Borg Scale (0 [Best] - 10 [Worst] ).

Secondary Outcome Measures:
  • Exercise Endurance Time [ Time Frame: 2 Weeks ]
    Difference in exercise endurance time between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.

Enrollment: 12
Study Start Date: December 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm 1: drug, crossing over to Pbo comparator
Drug: Fluticasone
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Arm 2: Pbo comparator, crossing over to drug
Drug: Fluticasone
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Drug: Comparator: Placebo
Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40 years and older
  • Clinical diagnosis of COPD for greater than one year
  • History of cigarette smoking

Exclusion Criteria:

  • Other lung diseases (not including COPD), such as asthma
  • A condition that could interfere with your ability to perform exercise tests
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00387036

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00387036     History of Changes
Other Study ID Numbers: 0000-036
Study First Received: October 5, 2006
Results First Received: April 8, 2010
Last Updated: December 17, 2015

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on May 25, 2017